Takeda Pharmaceutical has patented a method for treating perianal fistulizing Crohn’s disease using a humanized antibody targeting a4ß7 integrin. The dosing regimen includes initial and subsequent infusions, resulting in fistula closure and reduced PDAI score. Antibiotics are also administered during treatment. GlobalData’s report on Takeda Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Takeda Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Takeda Pharmaceutical's grant share as of January 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of perianal fistulizing crohn's disease with humanized antibody
See Also:
A recently granted patent (Publication Number: US11884731B2) discloses a method for treating perianal fistulizing Crohn's disease in human patients. The method involves administering a humanized antibody with binding specificity for human a4ß7 integrin to patients with moderately to severely active Crohn's disease who have not responded adequately to tumor necrosis factor-alpha antagonists. The dosing regimen includes an initial dose followed by subsequent doses every few weeks, with the aim of closing at least 50% of perianal draining fistulae and reducing the Perianal Disease Activity Index (PDAI) score by at least 3 points. The humanized antibody used in the treatment has specific antigen-binding regions and is administered alongside antibiotics during the initial weeks of treatment.
Furthermore, the patent claims cover variations in the method, such as patients with additional fistula types, measurement of fistula closure using MRI assessment, and the use of specific antibodies like vedolizumab. The method also addresses cases where patients have not responded to other treatments like azathioprine, 6-mercaptopurine, or methotrexate. Additionally, the patent details the specific sequences of the antibody's heavy and light chain variable regions, emphasizing the importance of the a4ß7 complex in the treatment process. Overall, the patent provides a comprehensive approach to treating perianal fistulizing Crohn's disease, offering a structured dosing regimen and specific criteria for evaluating treatment effectiveness.
To know more about GlobalData’s detailed insights on Takeda Pharmaceutical, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
